ALDEYRA THERAPEUTICS, INC. (ALDX) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$5.85M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$3.55M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$8.00M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$10.17M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$5.85M | (m) | (m) | (m) | (m) | -$4.59M* | (m) | $3.48M | (m) | (m) |
| 2026-03-31 | Reported | (m) | -$3.55M | (m) | (m) | (m) | (m) | -$5.11M | (m) | $2.41M | (m) | (m) |
| 2025-09-30 | Reported | (m) | -$8.00M | (m) | (m) | (m) | (m) | -$7.02M* | (m) | $5.43M | (m) | (m) |
| 2025-06-30 | Reported | (m) | -$10.17M | (m) | (m) | (m) | (m) | -$8.56M* | (m) | $8.51M | (m) | (m) |
| 2025-03-31 | Reported | (m) | -$10.43M | (m) | (m) | (m) | (m) | -$12.47M | (m) | $7.42M | (m) | (m) |
| 2024-09-30 | Reported | (m) | -$16.14M | (m) | (m) | (m) | (m) | -$7.97M* | (m) | $12.44M | (m) | (m) |
| 2024-06-30 | Reported | (m) | -$18.01M | (m) | (m) | (m) | (m) | -$13.22M* | (m) | $14.97M | (m) | (m) |
| 2024-03-31 | Reported | (m) | -$9.39M | (m) | (m) | (m) | (m) | -$9.97M | (m) | $6.18M | (m) | (m) |
| 2023-09-30 | Reported | (m) | -$9.55M | (m) | (m) | (m) | $0.00* | -$8.02M* | (m) | $6.96M | (m) | (m) |
| 2023-06-30 | Reported | (m) | -$10.34M | (m) | (m) | (m) | $0.00* | -$13.36M* | (m) | $6.96M | (m) | (m) |
| 2023-03-31 | Reported | (m) | -$16.80M | (m) | (m) | (m) | $0.00 | -$9.44M | (m) | $11.24M | (m) | (m) |
| 2022-09-30 | Reported | (m) | -$14.78M | (m) | (m) | (m) | $0.00* | -$12.57M* | (m) | $11.54M | (m) | (m) |
| 2022-06-30 | Reported | (m) | -$17.71M | (m) | (m) | (m) | $0.00* | -$19.96M* | (m) | $14.57M | (m) | (m) |
| 2022-03-31 | Reported | (m) | -$16.48M | (m) | (m) | (m) | $16.32K | -$12.87M | (m) | $12.23M | (m) | (m) |
| 2021-09-30 | Reported | (m) | -$15.44M | (m) | (m) | (m) | $0.00* | -$8.43M* | (m) | $12.89M | (m) | (m) |
| 2021-06-30 | Reported | (m) | -$14.54M | (m) | (m) | (m) | $0.00* | -$9.07M* | (m) | $11.47M | (m) | (m) |
| 2021-03-31 | Reported | (m) | -$10.83M | (m) | (m) | (m) | $7.81K | -$13.47M | (m) | $7.73M | (m) | (m) |
| 2020-09-30 | Reported | (m) | -$8.39M | (m) | (m) | (m) | $0.00* | -$6.24M* | (m) | $6.13M | (m) | (m) |
| 2020-06-30 | Reported | (m) | -$7.11M | (m) | (m) | (m) | (m) | -$7.58M* | (m) | $4.89M | (m) | (m) |
| 2020-03-31 | Reported | (m) | -$9.64M | (m) | (m) | (m) | (m) | -$15.36M | (m) | $6.63M | (m) | (m) |
| 2019-09-30 | Reported | (m) | -$19.02M | (m) | (m) | (m) | $0.00* | -$8.32M* | (m) | $16.22M | (m) | $0.00* |
| 2019-06-30 | Reported | (m) | -$13.73M | (m) | (m) | (m) | $4.60K* | -$12.81M* | (m) | $10.66M | (m) | $0.00* |
| 2019-03-31 | Reported | (m) | -$17.43M | (m) | (m) | (m) | $4.92K | -$12.63M | (m) | $7.85M | (m) | -$1.31M |
| 2018-09-30 | Reported | (m) | -$10.95M | (m) | (m) | (m) | $47.62K* | -$7.69M* | (m) | $7.88M | (m) | $0.00* |
| 2018-06-30 | Reported | (m) | -$9.17M | (m) | (m) | (m) | $61.76K* | -$6.25M* | (m) | $6.79M | (m) | $0.00* |
| 2018-03-31 | Reported | (m) | -$8.49M | (m) | (m) | (m) | $139.01K | -$7.95M | (m) | $6.60M | (m) | $0.00 |
| 2017-09-30 | Reported | (m) | -$5.02M | (m) | (m) | (m) | (m) | -$4.71M* | (m) | $3.54M | (m) | $0.00* |
| 2017-06-30 | Reported | (m) | -$5.33M | (m) | (m) | (m) | (m) | (m) | (m) | $3.85M | (m) | $0.00* |
| 2017-03-31 | Reported | (m) | -$5.10M | (m) | (m) | (m) | $11.59K | (m) | (m) | $3.37M | (m) | $0.00 |
| 2017-03-31 | Reported | (m) | -$5.10M | (m) | (m) | (m) | $11.59K | (m) | (m) | $3.37M | (m) | (m) |
| 2016-09-30 | Reported | (m) | -$4.78M | (m) | (m) | (m) | (m) | (m) | (m) | $3.38M | (m) | $0.00* |
| 2016-06-30 | Reported | (m) | -$4.30M | (m) | (m) | (m) | $2.58K* | (m) | (m) | $2.83M | (m) | $0.00* |
| 2016-03-31 | Reported | (m) | -$4.97M | (m) | (m) | (m) | $9.23K | (m) | (m) | $3.51M | (m) | $0.00 |
| 2015-09-30 | Reported | (m) | -$3.34M | (m) | (m) | (m) | $54.24K* | (m) | (m) | $2.08M | (m) | $0.00* |
| 2015-06-30 | Reported | (m) | -$2.20M | (m) | (m) | (m) | $30.43K* | (m) | (m) | $1.25M | (m) | $0.00* |
| 2015-03-31 | Reported | (m) | -$2.11M | (m) | (m) | (m) | $1.44K | (m) | (m) | $1.14M | (m) | $0.00 |
| 2014-09-30 | Reported | (m) | -$1.97M | (m) | (m) | (m) | (m) | (m) | (m) | $1.20M | (m) | $0.00* |
| 2014-06-30 | Reported | (m) | -$1.65M | (m) | (m) | (m) | (m) | (m) | (m) | $663.91K | (m) | $0.00* |
| 2014-03-31 | Reported | (m) | -$1.24M | (m) | (m) | (m) | (m) | (m) | (m) | $444.28K | (m) | $0.00 |
| 2013-09-30 | Reported | (m) | -$1.17M | (m) | (m) | (m) | (m) | (m) | (m) | $666.04K | (m) | (m) |
| 2013-06-30 | Reported | (m) | -$985.69K | (m) | (m) | (m) | (m) | (m) | (m) | $325.05K | (m) | (m) |
| 2013-03-31 | Reported | (m) | -$291.54K | (m) | (m) | (m) | (m) | (m) | (m) | $150.23K | (m) | (m) |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | -$35.27M | (m) | (m) | (m) | (m) | -$33.35M | (m) | $25.66M | (m) | $0.00 |
| 2024-12-31 | Reported | (m) | -$60.12M | (m) | (m) | (m) | (m) | -$43.21M | (m) | $48.22M | (m) | $1.00K |
| 2023-12-31 | Reported | (m) | -$42.79M | (m) | (m) | (m) | $0.00 | -$30.33M | (m) | $29.46M | (m) | $0.00 |
| 2022-12-31 | Reported | (m) | -$62.68M | (m) | (m) | (m) | $16.32K | -$56.64M | (m) | $47.31M | (m) | $0.00 |
| 2021-12-31 | Reported | (m) | -$56.22M | (m) | (m) | (m) | $7.81K | -$42.56M | (m) | $44.94M | (m) | $0.00 |
| 2020-12-31 | Reported | (m) | -$36.42M | (m) | (m) | (m) | (m) | -$37.49M | (m) | $24.68M | (m) | -$479.26K |
| 2019-12-31 | Reported | (m) | -$63.07M | (m) | (m) | (m) | $9.53K | -$44.98M | (m) | $44.35M | (m) | -$1.31M |
| 2018-12-31 | Reported | (m) | -$39.70M | (m) | (m) | (m) | $262.97K | -$29.86M | (m) | $29.82M | (m) | $0.00 |
| 2017-12-31 | Reported | (m) | -$22.49M | (m) | (m) | (m) | $24.76K | -$19.22M | (m) | $16.30M | (m) | $0.00 |
| 2016-12-31 | Reported | (m) | -$18.70M | (m) | (m) | (m) | $11.81K | (m) | (m) | $13.18M | (m) | $0.00 |
| 2016-12-31 | Reported | (m) | -$18.70M | (m) | (m) | (m) | $11.81K | (m) | (m) | $13.18M | (m) | (m) |
| 2015-12-31 | Reported | (m) | -$11.99M | (m) | (m) | (m) | $86.12K | (m) | (m) | $7.57M | (m) | $0.00 |
| 2014-12-31 | Reported | (m) | -$7.27M | (m) | (m) | (m) | $14.06K | (m) | (m) | $3.71M | (m) | $0.00 |
| 2013-12-31 | Reported | (m) | -$3.68M | (m) | (m) | (m) | (m) | (m) | (m) | $1.54M | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |